M. Conteh

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.

D. Watson-Jones, C. McLean, G. Deen, 2022, The Lancet. Infectious diseases.